Pfizer Licenses Chai Discovery’s AI Platform to Accelerate Biologics Research

Shots: Pfizer & Chai Discovery have entered into a licensing agreement, allowing Pfizer to integrate Chai’s AI-driven drug discovery platform into its biologics research workflows As per the deal, Pfizer will integrate Chai’s AI platform into its drug discovery engine, gaining early access to the Chai-3 model & a customized AI model built using Pfizer’s…

ByRidhi RastogiJune 5, 2026

NEWS

Lundbeck Partners with Cradle to Accelerate AI-Driven Biotherapeutics Discovery

Shots: Lundbeck and Cradle entered a partnership to leverage AI-powered protein engineering for the discovery and optimization of biotherapeutics, with an initial focus on 2 antibody programs targeting CNS diseases Lundbeck will deploy Cradle’s generative AI platform in its first end-to-end AI-guided protein engineering workflow, using iterative feedback from experimental data to discover & optimize…

ByRidhi RastogiJune 4, 2026

NEWS

Alnylam and Inceptive Enter ~$2B Collaboration to Accelerate AI-Powered Discovery of RNAi Therapeutics

Shots: Alnylam Pharmaceuticals & Inceptive Nucleics have entered into a strategic collaboration to accelerate the discovery of novel RNAi therapeutics The collaboration is valued at up to $2B, with $30M upfront, incl. cash & an equity investment in Inceptive. Inceptive will also receive additional preclinical, regulatory, & commercial milestone payments Collaboration combines Alnylam’s RNAi expertise…

ByRidhi RastogiJune 4, 2026

NEWS

NeuroPace Receives the US FDA Approval for ECoG Assistant to Advance AI-Driven Epilepsy Care

Shots: The US FDA has approved ECoG Assistant, an AI-powered clinician tool designed to support epilepsy management using data from the RNS System, with NeuroPace debuting the tool at ASSFN’26 ECoG Assistant was developed using 124,450 epileptologist-labeled intracranial EEG records & identifies ECoGs of Interest, enabling clinicians to review long-term EEG trends & circadian activity…

ByRidhi RastogiJune 1, 2026

NEWS

Cardiosense Receives FDA De Novo Classification for its PCWP Analysis Software

Shots: The FDA has granted De Novo classification to Cardiosense's PCWP Analysis Software to noninvasively estimate pulmonary capillary wedge pressure (PCWP) in adults with heart failure with reduced ejection fraction (HFrEF), incl. those with LVEF ≤40% & NYHA Class II, III & IV symptoms The Software integrates its CardioTag wearable sensor with AI to…

ByRidhi RastogiMay 28, 2026

NEWS

Myriad Genetics Launches Prolaris + AI Test for Personalized Prostate Cancer Active Surveillance

Shots: Myriad Genetics to launch the Prolaris + AI Test, with the new AI metric available for all Prolaris Biopsy Tests in the US from May 29, 2026 excl. New York; approval in NY is expected soon A validation study of 998 pts for model training & 296 pts for validation, demonstrated that AI-GUR independently…

ByRidhi RastogiMay 27, 2026

NEWS

Tempus AI Launches ArteraAI Prostate Test for Metastatic Prostate Cancer

Shots: Tempus AI has reported clinical launch of the ArteraAI Prostate Test (mHSPC), a CLIA-certified & CAP-accredited prognostic assay designed for pts with metastatic hormone-sensitive prostate cancer (mHSPC) ArteraAI Prostate Test (mHSPC) is an externally developed digital pathology algorithm clinically available through the Tempus AI ecosystem, with full platform integration to support personalized treatment decisions…

ByRidhi RastogiMay 22, 2026

NEWS

Incyte Expands Partnership with Genesis Molecular AI to Advance AI-Driven Drug Discovery

Shots: Incyte and Genesis have expanded their collaboration to accelerate the discovery of novel molecules for Incyte-selected targets by deploying Genesis’ GEMS molecular AI platform across a broader range of challenging targets in Incyte’s portfolio Incyte will provide experimental data to enhance GEMS’ capabilities, plus the companies will add ≥5 new targets, with options for…

ByRidhi RastogiMay 21, 2026

NEWS

QIAGEN Teams Up with NVIDIA to Advance AI-Driven Drug Discovery

Shots: QIAGEN to integrate its Digital Insights bioinformatics business with NVIDIA accelerated computing & the NVIDIA BioNeMo platform to strengthen AI applications in drug discovery Partnership leverages graph-based AI that apply retrieval & reasoning techniques across biomedical knowledge graphs to help researchers analyze complex biological data & validate AI-generated insights, supporting practical applications across the…

ByRidhi RastogiMay 20, 2026

NEWS

Isomorphic Labs Raises $2.1B in Series B Funding to Scale AI Drug Design Engine & Advance Pipeline

Shots: Isomorphic Labs has reported a $2.1B Series B financing round led by Thrive Capital, with participation from existing investors Alphabet & GV alongside new backers MGX, Temasek, CapitalG, & the UK Sovereign AI Fund The company plans to use the capital to further develop & deploy its AI-powered drug discovery platform, IsoDDE, accelerate internal…

ByRidhi RastogiMay 13, 2026

Pfizer Licenses Chai Discovery’s AI Platform to Accelerate Biologics Research

Lundbeck Partners with Cradle to Accelerate AI-Driven Biotherapeutics Discovery

Alnylam and Inceptive Enter ~$2B Collaboration to Accelerate AI-Powered Discovery of RNAi Therapeutics

NeuroPace Receives the US FDA Approval for ECoG Assistant to Advance AI-Driven Epilepsy Care

Cardiosense Receives FDA De Novo Classification for its PCWP Analysis Software

Myriad Genetics Launches Prolaris + AI Test for Personalized Prostate Cancer Active Surveillance

Tempus AI Launches ArteraAI Prostate Test for Metastatic Prostate Cancer

Incyte Expands Partnership with Genesis Molecular AI to Advance AI-Driven Drug Discovery

QIAGEN Teams Up with NVIDIA to Advance AI-Driven Drug Discovery

Isomorphic Labs Raises $2.1B in Series B Funding to Scale AI Drug Design Engine & Advance Pipeline

Contact US

FOLLOW US